Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO: Rivaroxaban vs Antiplatelet after TAVR
NCT02556203Phase 3Terminated
- Sponsor
- Bayer
- Start
- Dec 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of rivaroxaban in thromboembolism, sponsored by Bayer. Started Dec 2015; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02556203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556203.